Terms: = Pancreatic cancer AND CASP8, ALPS2B, 841, ENSG00000064012, MGC78473, CAP4, MACH, MCH5, FLICE AND Treatment
42 results:
1. Predicting the unpredictable: a robust nomogram for predicting recurrence in patients with ampullary carcinoma.
Chen R; Zhu L; Zhang Y; Cui D; Chen R; Guo H; Peng L; Xiao C
BMC Cancer; 2024 Feb; 24(1):212. PubMed ID: 38360582
[TBL] [Abstract] [Full Text] [Related]
2. MRI-Based Radiomics Nomogram for Preoperatively Differentiating Intrahepatic Mass-Forming Cholangiocarcinoma From Resectable Colorectal Liver Metastases.
Xu Y; Ye F; Li L; Yang Y; Ouyang J; Zhou Y; Wang S; Xie L; Zhou J; Zhao H; Zhao X
Acad Radiol; 2023 Sep; 30(9):2010-2020. PubMed ID: 37414635
[TBL] [Abstract] [Full Text] [Related]
3. Herniarin-loaded solid lipid nanoparticles: promising molecular mechanism and therapeutic potential against pancreatic cancer line.
Delkhah AMD; Karimi E; Farivar S
Mol Biol Rep; 2023 Aug; 50(8):6469-6479. PubMed ID: 37326747
[TBL] [Abstract] [Full Text] [Related]
4. Estimated tumor blood flow as a predictive imaging indicator of therapeutic response in pancreatic ductal adenocarcinoma: use of three-phase contrast-enhanced computed tomography.
Maehira H; Tsuji Y; Iida H; Mori H; Nitta N; Maekawa T; Kaida S; Miyake T; Tani M
Int J Clin Oncol; 2022 Feb; 27(2):373-382. PubMed ID: 34783936
[TBL] [Abstract] [Full Text] [Related]
5. Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis.
Lee YS; Lee JC; Kim JH; Kim J; Hwang JH
Sci Rep; 2021 Oct; 11(1):20152. PubMed ID: 34635731
[TBL] [Abstract] [Full Text] [Related]
6. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Kharat AA; Nelson R; Au T; Biskupiak J
J Manag Care Spec Pharm; 2021 Oct; 27(10):1367-1375. PubMed ID: 34595948
[No Abstract] [Full Text] [Related]
7. Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Sigel K; Zhou M; Park YA; Mutetwa T; Nadkarni G; Yeh C; Polak P; Sigel C; Conroy T; Juzyna B; Ychou M; Fojo T; Wisnivesky JP; Bates SE
Semin Oncol; 2021 Feb; 48(1):69-75. PubMed ID: 33714591
[TBL] [Abstract] [Full Text] [Related]
8. Metformin and Gastrointestinal cancer Development in Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea.
You JH; Song SO; Kang MJ; Cho YY; Kim SW; Suh SH; Lee S; Lee YH; Lee BW
Clin Transl Gastroenterol; 2020 Nov; 11(11):e00254. PubMed ID: 33105165
[TBL] [Abstract] [Full Text] [Related]
9. Applying a radiomics-based strategy to preoperatively predict lymph node metastasis in the resectable pancreatic ductal adenocarcinoma.
Liu P; Gu Q; Hu X; Tan X; Liu J; Xie A; Huang F
J Xray Sci Technol; 2020; 28(6):1113-1121. PubMed ID: 33074215
[TBL] [Abstract] [Full Text] [Related]
10. Outcomes of Patients With Advanced Gastrointestinal cancer in Relationship to Opioid Use: Findings From Eight Clinical Trials.
Abdel-Rahman O; Karachiwala H; Easaw JC
J Natl Compr Canc Netw; 2020 May; 18(5):575-581. PubMed ID: 32380454
[TBL] [Abstract] [Full Text] [Related]
11. Vanadium: Risks and possible benefits in the light of a comprehensive overview of its pharmacotoxicological mechanisms and multi-applications with a summary of further research trends.
Ścibior A; Pietrzyk Ł; Plewa Z; Skiba A
J Trace Elem Med Biol; 2020 Sep; 61():126508. PubMed ID: 32305626
[TBL] [Abstract] [Full Text] [Related]
12. Nomograms predict survival outcomes for distant metastatic pancreatic neuroendocrine tumor: A population based STROBE compliant study.
Li G; Tian ML; Bing YT; Wang HY; Yuan CH; Xiu DR
Medicine (Baltimore); 2020 Mar; 99(13):e19593. PubMed ID: 32221079
[TBL] [Abstract] [Full Text] [Related]
13. Relationship between SDC1 and cadherin signalling activation in cancer.
Liao S; Liu C; Zhu G; Wang K; Yang Y; Wang C
Pathol Res Pract; 2020 Jan; 216(1):152756. PubMed ID: 31810587
[TBL] [Abstract] [Full Text] [Related]
14. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Liao W; Huang J; Zhu G; Zhou J; Wen F; Zhang P; Zhou K; Wu Q; Wang X; Gou H; Li Q
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):133-138. PubMed ID: 31597496
[No Abstract] [Full Text] [Related]
15. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL; Rørth R; Jhund PS; Docherty KF; Sattar N; Preiss D; Køber L; Petrie MC; McMurray JJV
Lancet Diabetes Endocrinol; 2019 Oct; 7(10):776-785. PubMed ID: 31422062
[TBL] [Abstract] [Full Text] [Related]
16. Adjuvant chemotherapy versus chemoradiation in high-risk pancreatic adenocarcinoma: A propensity score-matched analysis.
Raoof M; Blakely AM; Melstrom LG; Lee B; Warner SG; Chung V; Singh G; Chen YJ; Fong Y
Cancer Med; 2019 Oct; 8(13):5881-5890. PubMed ID: 31414566
[TBL] [Abstract] [Full Text] [Related]
17. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic pancreatic Adenocarcinoma (ECLIPSE Study).
Le DT; Picozzi VJ; Ko AH; Wainberg ZA; Kindler H; Wang-Gillam A; Oberstein P; Morse MA; Zeh HJ; Weekes C; Reid T; Borazanci E; Crocenzi T; LoConte NK; Musher B; Laheru D; Murphy A; Whiting C; Nair N; Enstrom A; Ferber S; Brockstedt DG; Jaffee EM
Clin Cancer Res; 2019 Sep; 25(18):5493-5502. PubMed ID: 31126960
[TBL] [Abstract] [Full Text] [Related]
18. PET/CT in brachytherapy early response evaluation of pancreatic ductal adenocarcinoma xenografts: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging.
Liu Y; Liu M; Liu X; Zhou Y
Abdom Radiol (NY); 2019 Mar; 44(3):950-957. PubMed ID: 30315322
[TBL] [Abstract] [Full Text] [Related]
19. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
Conemans EB; Lodewijk L; Moelans CB; Offerhaus GJA; Pieterman CRC; Morsink FH; Dekkers OM; de Herder WW; Hermus AR; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Brosens LAA; Dreijerink KMA; Borel Rinkes IHM; Timmers HTM; Valk GD; Vriens MR
Eur J Endocrinol; 2018 Sep; 179(3):153-160. PubMed ID: 29903750
[TBL] [Abstract] [Full Text] [Related]
20. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
[TBL] [Abstract] [Full Text] [Related]
[Next]
